Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could magnetic pulses to the brain ease IBS pain?

NCT ID NCT07345377

Symptom relief Sponsor: The Affiliated Hospital of Hangzhou Normal University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study explores whether individualized transcranial magnetic stimulation (TMS) can improve symptoms in adults with irritable bowel syndrome (IBS). Participants receive 10 TMS sessions over two weeks, with brain scans and stool tests before and after to understand how the treatment affects brain-gut connections. The goal is to see if this non-invasive approach reduces pain and discomfort, and whether tests can predict who will benefit.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
individualized transcranial magnetic stimulation (TMS)
What this could lead to
If it works, this could point toward a non-invasive, drug-free treatment for irritable bowel syndrome that targets brain-gut connections.
What could go wrong
This is an early exploratory study with no control group, so results may not prove effectiveness. TMS is generally safe but can cause mild scalp discomfort or headache.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 160 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2022

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Meets the Rome IV diagnostic criteria for Irritable Bowel Syndrome (IBS); * Has discontinued IBS-related medications for more than 2 weeks prior to enrollment; * Aged between 18 and 75 years (inclusive); * Has sufficient cognitive ability to provide informed consent, understand study instructions, and complete questionnaires. Exclusion Criteria: * Has contraindications to MRI (e.g., metal implants in the body, claustrophobia) or TMS (e.g., history of epilepsy, skull defects); * Diagnosed with mental illnesses (e.g., schizophrenia, bipolar disorder) that require ongoing medication or psychotherapy; * Women who are pregnant, breastfeeding, or planning to become pregnant during the study period; * Presents signs of severe illness requiring hospitalization (e.g., hemodynamic instability, acute infection, acute myocardial infarction, cerebral infarction); * Has taken any substances that may affect study indicators (e.g., probiotics, prebiotics) within 3 months prior to enrollment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Depressive disorder, major, moderate are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

depressive disorder follicular lymphoma irritable bowel syndrome major depressive disorder Pain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Depressive disorder, major, moderate Irritable bowel syndrome (IBS) Pain

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The affiliated hospital of Hangzhou Normal University

    Hangzhou, Zhejiang, 310015, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.